Review: Beyond KRAS: perspectives on new potential markers of intrinsic and acquired resistance to epidermal growth factor receptor inhibitors in metastatic colorectal cancer
Free accessReview articleFirst published online November, 2009
Review: Beyond KRAS: perspectives on new potential markers of intrinsic and acquired resistance to epidermal growth factor receptor inhibitors in metastatic colorectal cancer
The monoclonal antibodies cetuximab and panitumumab, directed against the epidermal growth factor receptor (EGFR), are licensed for the treatment of KRAS wild-type metastatic colorectal cancer (mCRC). Such ‘molecular restriction’ derived from post-hoc analyses of randomized trials and from other retrospective series all indicate how tumors bearing KRAS (v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations are resistant to EGFR inhibition. Even if highly sensitive for nonresponse, KRAS testing is not very specific. In fact, a limited but still considerable proportion of KRAS wild-type patients rapidly progress on treatment with an EGFR inhibitor. New potential molecular determinants of benefit from such treatment are under investigation and may further refine the selection of patients. Pharmacogenomic analyses and translational studies are also ongoing for exploring the field of acquired resistance to anti-EGFRs, since all patients eventually progress. New biological data are awaited for optimizing the use of molecular agents in colorectal cancer and for identifying promising targets that could allow to better understand and, potentially, overcome mechanisms of primary or secondary resistance to EGFR inhibitors.
Albitar, M., Yeh, C. and Ma, W.(2009) K-Ras mutations and cetuximab in colorectal cancer. N Engl J Med360: 834.
2.
Allegra, C.J., Jessup, J.M., Somerfield, M.R., Hamilton, S.R., Hammond, E.H., Hayes, D.F. et al. (2009) American Society of Clinical Oncology Provisional Clinical Opinion: Testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol27: 2091-2096.
3.
Amado, R.G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D.J. et al. (2008) Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol26: 1626-1634.
4.
Amador, M., Oppenheimer, D., Perea, S. and Maitra, A. ( 2004) An epidermal growth factor receptor intron 1 polymoprhism mediates response to epidermal growth factor receptor inhibitors. Cancer Res64: 9139-9143.
5.
Andreyev, H.J., Norman, A.R., Cunningham, D., Oates, J., Dix, B.R., Iacopetta, B.J. et al. (2001) Kirsten RAS mutations in patients with colorectal cancer: the ‘Rascal II’ study. Br J Cancer85: 692-696.
6.
Anon. (2008) Committee for medicinal products for human use post-authorisation summary of positive opinion for Erbitux. Available at: http://www.emea.europa.eu/pdfs/human/opinion/Erbitux_28040208en.pdf.
7.
Atkins, D., Reiffen, K.A., Tegtmeier, C.L., Winther, H., Bonato, M.S. and Storkel, S. ( 2004) Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues: variation in staining intensity due to choice of fixative and storage time of tissue sections. J Histochem Cytochem52: 893-901.
8.
Benavente, S., Huang, S., Armstrong, E.A., Chi, A., Hsu, K.T., Wheeler, D.L. et al. (2009) Establishment and characterization of a model of acquired resistance to epidermal growth factor receptor targeting agents in human cancer cells. Clin Cancer Res15: 1585-1592.
9.
Benvenuti, S., Sartore-Bianchi, A., Di Nicolantonio, F., Zanon, C., Moroni, M., Veronese, S. et al. (2007) Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res67: 2643-2648.
10.
Bianco, R., Garofalo, S., Rosa, R., Damiano, V., Gelardi, T., Daniele, G. et al. (2008) Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs. Br J Cancer98: 923-930.
11.
Bianco, R., Rosa, R., Damiano, V., Daniele, G., Gelardi, T., Garofalo, S. et al. (2008) Vascular endothelial growth factor receptor-1 contributes to resistance to anti-epidermal growth factor receptor drugs in human cancer cells. Clin Cancer Res14: 5069-5080.
12.
Bibeau, F., Lopez-Crapez, E., Di Fiore, F., Thezenas, S., Ychou, M., Blanchard, F. et al. (2009) Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol27: 1122-1129.
13.
Biscardi, J.S., Maa, M.C., Tice, D.A., Cox, M.E., Leu, T.H. and Parsons, S.J. ( 1999) C-Src-mediated phosphorylation of the epidermal growth factor receptor on Tyr845 and Tyr1101 is associated with modulation of receptor function. J Biol Chem274: 8335-8343.
14.
Bokemeyer, C., Bondarenko, I., Makhson, A., Hartmann, J.T., Aparicio, J., De Braud, F. et al. (2009) Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol27: 663-671.
15.
Bruns, C.J., Solorzano, C.C., Harbison, M.T., Ozawa, S., Tsan, R., Fan, D. et al. (2000) Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res60: 2926-2935.
16.
Buhrman, G., Wink, G. and Mattos, C. ( 2007) Transformation efficiency of RASq61 mutants linked to structural features of the switch regions in the presence of RAF. Structure15: 1618-1629.
17.
Chakravarti, A., Loeffler, J.S. and Dyson, N.J. ( 2002) Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling . Cancer Res62: 200-207.
18.
Chung, K.Y., Shia, J., Kemeny, N.E., Shah, M., Schwartz, G.K., Tse, A. et al. (2005) Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol23: 1803-1810.
19.
Ciardiello, F., Bianco, R., Caputo, R., Damiano, V., Troiani, T., Melisi, D. et al. (2004) Antitumor activity of Zd6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. Clin Cancer Res10: 784-793.
20.
Ciardiello, F., Bianco, R., Damiano, V., Fontanini, G., Caputo, R., Pomatico, G. et al. (2000) Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human geo colon cancer cells. Clin Cancer Res6: 3739-3747.
21.
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A. et al. (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med351: 337-345.
22.
De Roock, W., Lambrechts, D. and Tejpar, S.(2009) K-RAS mutations and cetuximab in colorectal cancer. N Engl J Med360: 834.
23.
De Roock, W., Piessevaux, H., De Schutter, J., Janssens, M., De Hertogh, G., Personeni, N. et al. (2007) KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol19: 508-515.
24.
Di Fiore, F., Blanchard, F., Charbonnier, F., Le Pessot, F., Lamy, A., Galais, M.P. et al. (2007) Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by cetuximab plus chemotherapy. Br J Cancer96: 1166-1169.
25.
Di Nicolantonio, F., Martini, M., Molinari, F., Sartore-Bianchi, A., Arena, S., Saletti, P. et al. (2008) Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol26: 5705-5712.
26.
Edkins, S., O’Meara, S., Parker, A., Stevens, C., Reis, M., Jones, S. et al. (2006) Recurrent KRAS codon 146 mutations in human colorectal cancer. Cancer Biol Ther5: 928-932.
27.
Faul, M.M., Gillig, J.R., Jirousek, M.R., Ballas, L.M., Schotten, T., Kahl, A. et al. (2003) Acyclic N-(azacycloalkyl)bisindolylmaleimides: isozyme selective inhibitors of PKCbeta. Bioorg Med Chem Lett13: 1857-1859.
28.
Frattini, M., Saletti, P., Romagnani, E., Martin, V., Molinari, F., Ghisletta, M. et al. (2007) PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer97: 1139-1145.
29.
Garm Spindler, K.L., Pallisgaard, N., Rasmussen, A.A., Lindebjerg, J., Andersen, R.F., Cruger, D. et al. (2009) The importance of KRAS mutations and EGF61A > G polymorphism to the effect of cetuximab and irinotecan in metastatic colorectal cancer . Ann Oncol20: 879-884.
30.
Gebhardt, F., Zanker, K.S. and Brandt, B. ( 1999) Modulation of epidermal growth factor receptor gene transcription by a polymorphic dinucleotide repeat in intron 1. J Biol Chem274: 13176-13180.
31.
Gelardi, T., Caputo, R., Damiano, V., Daniele, G., Pepe, S., Ciardiello, F. et al. (2008) Enzastaurin inhibits tumours sensitive and resistant to anti-EGFR drugs. Br J Cancer99: 473-480.
32.
Goel, A., Arnold, C., Niedzwiecki, D., Carethers, J., Dowell, J., Wasserman, L. et al. (2004) Frequent inactivation of PTEN by promoter hypermethylation in microsatellite instability-high sporadic colorectal cancers. Cancer Res64: 3014-3021.
33.
Graziano, F., Ruzzo, A., Loupakis, F., Canestrari, E., Santini, D., Catalano, V. et al. (2008) Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer . J Clin Oncol26: 1427-1434.
34.
Hebbar, M., Wacrenier, A., Desauw, C., Romano, O., Cattan, S., Triboulet, J.P. et al. (2006) Lack of usefulness of epidermal growth factor receptor expression determination for cetuximab therapy in patients with colorectal cancer. Anticancer Drugs17: 855-857.
35.
Hecht, J.R., Mitchell, E., Chidiac, T., Scroggin, C., Hagenstad, C., Spigel, D. et al. (2009) A randomized phase IIIb trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol27: 672-680.
36.
Herbst, R.S. and Shin, D.M. ( 2002) Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer94: 1593-1611.
37.
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W. et al. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med350: 2335-2342.
38.
Jhawer, M., Goel, S., Wilson, A.J., Montagna, C., Ling, Y.H., Byun, D.S. et al. (2008) PIK3ca mutation/ PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. Cancer Res68: 1953-1961.
39.
Jimeno, A., Messersmith, W.A., Hirsch, F.R., Franklin, W.A. and Eckhardt, S.G.(2009) KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection . J Clin Oncol27: 1130-1136.
40.
Jonker, D.J., O’Callaghan, C.J., Karapetis, C.S., Zalcberg, J.R., Tu, D., Au, H.J. et al. (2007) Cetuximab for the treatment of colorectal cancer . N Engl J Med357: 2040-2048.
41.
Karapetis, C.S., Khambata-Ford, S., Jonker, D.J., O’Callaghan, C.J., Tu, D., Tebbutt, N.C. et al. (2008) K-RAS mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med359: 1757-1765.
42.
Kawaguchi, Y., Kono, K., Mimura, K., Sugai, H., Akaike, H. and Fujii, H. ( 2007) Cetuximab induce antibody-dependent cellular cytotoxicity against EGFR-expressing esophageal squamous cell carcinoma. Int J Cancer120: 781-787.
43.
Khambata-Ford, S., Garrett, C.R., Meropol, N.J., Basik, M., Harbison, C.T., Wu, S. et al. (2007) Expression of epiregulin and amphiregulin and K-RAS mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol25: 3230-3237.
44.
Lievre, A., Bachet, J.B., Boige, V., Cayre, A., Le Corre, D., Buc, E. et al. (2008) KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab . J Clin Oncol26: 374-379.
45.
Lievre, A., Bachet, J.B., Le Corre, D., Boige, V., Landi, B., Emile, J.F. et al. (2006) KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res66: 3992-3995.
46.
Linardou, H., Dahabreh, I., Kanaloupiti, D., Siannis, F., Bafaloukos, D., Kosmidis, P. et al. (2008) Assessment of somatic K-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol9: 962-972.
47.
Loupakis, F., Pollina, L., Stasi, I., Ruzzo, A., Scartozzi, M., Santini, D. et al. (2009) PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J Clin Oncol27: 2622-2629.
48.
Lu, K., Mcguire, J.J., Slocum, H.K. and Rustum, Y.M. ( 1997) Mechanisms of acquired resistance to modulation of 5-fluorouracil by leucovorin in HCT-8 human ileocecal carcinoma cells. Biochem Pharmacol53: 689-696.
49.
Lurje, G., Nagashima, F., Zhang, W., Yang, D., Chang, H.M., Gordon, M.A. et al. (2008) Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-RAS in metastatic colorectal cancer patients treated with single-agent cetuximab. Clin Cancer Res14: 7884-7895.
50.
Moriai, T., Kobrin, M.S., Hope, C., Speck, L. and Korc, M. ( 1994) A variant epidermal growth factor receptor exhibits altered type alpha transforming growth factor binding and transmembrane signaling . Proc Natl Acad Sci U S A91: 10217-10221.
51.
Moroni, M., Veronese, S., Benvenuti, S., Marrapese, G., Sartore-Bianchi, A., Di Nicolantonio, F. et al. (2005) Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol6: 279-286.
52.
Niwa, R., Hatanaka, S., Shoji-Hosaka, E., Sakurada, M., Kobayashi, Y., Uehara, A. et al. (2004) Enhancement of the antibody-dependent cellular cytotoxicity of low-fucose IGGL is independent of FcgammarIIIa functional polymorphism. Clin Cancer Res10: 6248-6255.
53.
Oden-Gangloff, A., Di Fiore, F., Bibeau, F., Lamy, A., Bougeard, G., Charbonnier, F. et al. (2009) Tp53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy. Br J Cancer100: 1330-1335.
54.
Ogino, S., Kawasaki, T., Brahmandam, M., Yan, L., Cantor, M., Namgyal, C. et al. (2005) Sensitive sequencing method for KRAS mutation detection by pyrosequencing. J Mol Diagn7: 413-421.
55.
Ogino, S., Nosho, K., Kirkner, G.J., Shima, K., Irahara, N., Kure, S. et al. (2009) PIK3ca mutation is associated with poor prognosis among patients with curatively resected colon cancer. J Clin Oncol27: 1477-1484.
56.
Perrone, F., Lampis, A., Orsenigo, M., Di Bartolomeo, M., Gevorgyan, A., Losa, M. et al. (2008) PI3KCA/ PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. Ann Oncol20: 84-90.
57.
Perrotte, P., Matsumoto, T., Inoue, K., Kuniyasu, H., Eve, B.Y., Hicklin, D.J. et al. (1999) Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin Cancer Res5: 257-265.
58.
Petit, A.M., Rak, J., Hung, M.C., Rockwell, P., Goldstein, N., Fendly, B. et al. (1997) Neutralizing antibodies against epidermal growth factor and ERBB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol151: 1523-1530.
59.
Piette, J., Neel, H. and Marechal, V. ( 1997) MDM2: keeping P53 under control. Oncogene15: 1001-1010.
60.
Pintilie, M., Iakovlev, V., Fyles, A., Hedley, D., Milosevic, M. and Hill, R.P.(2009) Heterogeneity and power in clinical biomarker studies. J Clin Oncol27: 1517-1521.
61.
Prenen, H., De Schutter, J., Jacobs, B., De Roock, W., Biesmans, B., Claes, B. et al. (2009) PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer. Clin Cancer Res15: 3184-3188.
62.
Rajagopalan, H., Bardelli, A., Lengauer, C., Kinzler, K.W., Vogelstein, B. and Velculescu, V.E. ( 2002) Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status . Nature418: 934.
63.
Rodriguez-Viciana, P., Tetsu, O., Oda, K., Okada, J., Rauen, K. and Mccormick, F. ( 2005) Cancer targets in the RAS pathway. Cold Spring Harb Symp Quant Biol70: 461-467.
64.
Saltz, L.B., Lenz, H.J., Kindler, H.L., Hochster, H.S., Wadler, S., Hoff, P.M. et al. (2007) Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the bond-2 study. J Clin Oncol25: 4557-4561.
65.
Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S. et al. (2004) High frequency of mutations of the PIK3CA gene in human cancers. Science304: 554.
66.
Sartore-Bianchi, A., Martini, M., Molinari, F., Veronese, S., Nichelatti, M., Artale, S. et al. (2009) PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res69: 1851-1857.
67.
Sartore-Bianchi, A., Moroni, M., Veronese, S., Carnaghi, C., Bajetta, E., Luppi, G. et al. (2007) Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab . J Clin Oncol25: 3238-3245.
68.
Scartozzi, M., Bearzi, I., Berardi, R., Mandolesi, A., Fabris, G. and Cascinu, S. ( 2004) Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies . J Clin Oncol22: 4772-4778.
69.
Shahbazi, M., Pravica, V., Nasreen, N., Fakhoury, H., Fryer, A.A., Strange, R.C. et al. (2002) Association between functional polymorphism in EGF gene and malignant melanoma. Lancet359: 397-401.
70.
Simi, L., Pratesi, N., Vignoli, M., Sestini, R., Cianchi, F., Valanzano, R. et al. (2008) High-resolution melting analysis for rapid detection of KRAS, BRAF, and PIK3CA gene mutations in colorectal cancer. Am J Clin Pathol130: 247-253.
71.
Sobrero, A.F., Maurel, J., Fehrenbacher, L., Scheithauer, W., Abubakr, Y.A., Lutz, M.P. et al. (2008) EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol26: 2311-2319.
72.
Tejpar, S., De Roock, W., Biesmans, B., De Schutter, J., Piessevaux, H., Humblet, Y. et al. (2008) High amphiregulin and epiregulin expression in KRAS wild type colorectal primaries predicts response and survival benefit after treatment with cetuximab and irinotecan for metastatic disease. Proceedings 2008 Gastrointestinal Cancers Symposium Abstr. 411.
73.
Tice, D.A., Biscardi, J.S., Nickles, A.L. and Parsons, S.J. ( 1999) Mechanism of biological synergy between cellular SRC and epidermal growth factor receptor. Proc Natl Acad Sci U S A96: 1415-1420.
74.
Tol, J., Dijkstra, J.R., Vink-Borger, M.E., Nagtegaal, I.D., Punt, C.J., Van Krieken, J.H. et al. (2009b) High sensitivity of both sequencing and real-time PCR analysis of KRAS mutations in colorectal cancer tissue. J Cell Mol Med: in press.
75.
Tol, J., Koopman, M., Cats, A., Rodenburg, C.J., Creemers, G.J., Schrama, J.G. et al. (2009a) Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med360: 563-572.
76.
Van Cutsem, E., Kohne, C.H., Hitre, E., Zaluski, J., Chang Chien, C.R., Makhson, A. et al. (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med360: 1408-1417.
77.
Van Cutsem, E., Peeters, M., Siena, S., Humblet, Y., Hendlisz, A., Neyns, B. et al. (2007) Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol25: 1658-1664.
78.
Van Heek, N.T., Clayton, S.J., Sturm, P.D., Walker, J., Gouma, D.J., Noorduyn, L.A. et al. (2005) Comparison of the novel quantitative arms assay and an enriched PCR-ASO assay for K-RAS mutations with conventional cytology on endobiliary brush cytology from 312 consecutive extrahepatic biliary stenoses . J Clin Pathol58: 1315-1320.
79.
Van Krieken, J.H., Jung, A., Kirchner, T., Carneiro, F., Seruca, R., Bosman, F.T. et al. (2009) KRAS mutation testing for predicting response to Anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program. Virchows Arch454: 233-235.
80.
Van Royen-Kerkhof, A., Sanders, E.A., Wijngaarden, S., Van Roon, J.A., Voorhorst-Ogink, M. et al. (2004) Flow cytometric determination of FcgammarIIa (Cd32) polymorphism. J Immunol Methods294: 135-144.
81.
Viloria-Petit, A., Crombet, T., Jothy, S., Hicklin, D., Bohlen, P., Schlaeppi, J.M. et al. (2001) Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res61: 5090-5101.
82.
Wan, P.T., Garnett, M.J., Roe, S.M., Lee, S., Niculescu-Duvaz, D., Good, V.M. et al. (2004) Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell116: 855-867.
83.
Westra, J.L., Schaapveld, M., Hollema, H., De Boer, J.P., Kraak, M.M., De Jong, D. et al. (2005) Determination of Tp53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients. J Clin Oncol23: 5635-5643.
84.
Wheeler, D.L., Huang, S., Kruser, T.J., Nechrebecki, M.M., Armstrong, E.A., Benavente, S. et al. (2008) Mechanisms of acquired resistance to cetuximab: role of HER (ERBB) family members. Oncogene27: 3944-3956.
85.
Wheeler, D.L., Iida, M., Kruser, T.J., Nechrebecki, M.M., Dunn, E.F., Armstrong, E.A. et al. (2009) Epidermal growth factor receptor cooperates with SRC family kinases in acquired resistance to cetuximab. Cancer Biol Ther8: 696-703.
86.
Xu, K. and Shu, H.K. ( 2007) EGFR activation results in enhanced cyclooxygenase-2 expression through P38 mitogen-activated protein kinase-dependent activation of the Sp1/Sp3 transcription factors in human gliomas. Cancer Res67: 6121-6129.
87.
Zhang, W., Gordon, M., Schultheis, A.M., Yang, D.Y., Nagashima, F., Azuma, M. et al. (2007) Fcgr2a and Fcgr3a polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol25: 3712-3718.
88.
Zhou, X.P., Loukola, A., Salovaara, R., Nystrom-Lahti, M., Peltomaki, P., De LaChapelle, A. et al. (2002) PTEN mutational spectra, expression levels, and subcellular localization in microsatellite stable and unstable colorectal cancers. Am J Pathol161: 439-447.
